Dimension, a young venture capital firm at the vanguard of biotechnology’s embrace of artificial intelligence, has closed its biggest fund to date.
The firm on Tuesday announced it raised $800 million for “Dimension III,” its third fund since publicly launching in 2023. Dimension now manages $1.65 billion in assets and has supported 35 companies, its founders said in a statement.
Dimension is led by former Lux Capital general partners Adam Goulburn and Zavain Dar, as well as ex-Obvious Ventures managing director Nan Li. The firm has leaned heavily into what it’s referred to as the “digitization” of drugmaking, contending since starting up that high-powered computing tools are becoming increasingly enmeshed in the discovery of new medicines and creating new biotechs staffed with as many computer scientists as biologists.
That focus has put Dimension at the forefront of a dizzying sprint by drug companies small and large to deploy AI across their operations. Though there’s still plenty of skepticism about the ultimate impact AI will have on drug development, over the last year or so, giants like Eli Lilly, Roche, Takeda Pharmaceutical and Bristol Myers Squibb have teamed with tech leaders such as OpenAI and Nvidia to build supercomputers and help speed their work.
Simultaneously, fast-growing AI drug discovery upstarts such as Isomorphic Labs and Chai Discovery have commanded multibillion-dollar valuations in some of the year’s largest venture fundings. A recent report from HSBC’s Innovation Banking division noted how, compared to last year, all sectors of healthcare are currently on a quicker investment pace. The “prevalence of AI” has brought in new investors and “stirred discussion” on the role large AI tech companies will play going forward, the report said.
In its statement, Dimension’s own founders claimed they “underestimated” the speed of AI's “rapid ascent” and resulting blurring of lines between science and computing. “Timelines we predicted on the orders or years [were] compressed to months,” they wrote. “We hold strong conviction that the current moment, the right now, is singular in history.”
Dimension has partaken in that cross-sector convergence through investments it said ranged from the “single digit millions” to $50 million-plus and across stages of development. The firm co-led the seed funding for Chai, led the Series A financing for longevity startup NewLimit and participated in a $787 million Series C for AI-powered cancer and immune drugmaker Earendil Labs.
Dimension also spearheaded a “crossover” round for Odyssey Therapeutics and then helped anchor the company’s $279 million initial public offering in May. In 2024, Dimension led a follow-on financing for Monte Rosa Therapeutics, a publicly traded maker of “molecular glue” drugs.
The firm has seen one of its portfolio companies acquired, too. In April, a stealthy startup it backed, Coefficient Labs, was acquired by AI giant Anthropic for $400 million.
